AVLSA
Atlas Venture Life Science Advisors’s Dyne Therapeutics DYN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $86.9M | Hold |
9,130,465
| – | – | 13.12% | 3 |
|
|
2025
Q1 | $95.5M | Buy |
9,130,465
+1,111,111
| +14% | +$11.6M | 18.3% | 3 |
|
|
2024
Q4 | $189M | Sell |
8,019,354
-782
| -0% | -$18.4K | 23.05% | 2 |
|
|
2024
Q3 | $288M | Hold |
8,020,136
| – | – | 26.71% | 1 |
|
|
2024
Q2 | $283M | Hold |
8,020,136
| – | – | 29.8% | 1 |
|
|
2024
Q1 | $228M | Sell |
8,020,136
-1,865,313
| -19% | -$53M | 21.01% | 1 |
|
|
2023
Q4 | $131M | Hold |
9,885,449
| – | – | 15.66% | 3 |
|
|
2023
Q3 | $88.6M | Hold |
9,885,449
| – | – | 13.72% | 3 |
|
|
2023
Q2 | $111M | Hold |
9,885,449
| – | – | 13.84% | 3 |
|
|
2023
Q1 | $114M | Buy |
9,885,449
+15,966
| +0.2% | +$184K | 15.42% | 2 |
|
|
2022
Q4 | $114M | Buy |
9,869,483
+934,581
| +10% | +$10.8M | 13.78% | 3 |
|
|
2022
Q3 | $113M | Hold |
8,934,902
| – | – | 12.52% | 4 |
|
|
2022
Q2 | $61.4M | Hold |
8,934,902
| – | – | 10.26% | 3 |
|
|
2022
Q1 | $86.1M | Hold |
8,934,902
| – | – | 10.89% | 2 |
|
|
2021
Q4 | $106M | Buy |
+8,934,902
| New | +$106M | 9.76% | 3 |
|